**To the Editor,**

Approximately 5% of coronavirus disease (COVID-19) patients will require admission to an intensive care unit (ICU).[@CR1] Among these patients, the most severe cases may be mediated by a late-onset systemic inflammatory response with cytokine dysregulation referred to as cytokine release syndrome (CRS).[@CR2] Clinically, this results in fever, acute respiratory distress syndrome, multiorgan failure, and/or hemodynamic collapse due to distributive shock. Late-onset severe COVID-19 patients may respond to anti-inflammatory therapy without worsening the initial early viral infection.[@CR3] We describe a case series of 15 COVID-19 patients admitted to ICU who received corticosteroids in the context of CRS. Cytokine release syndrome was identified as worsening hypoxemia or vasoplegia with rising C-reactive protein (CRP) or interleukin-6 levels without alternative clinical explanation. The Research Ethics Board at our local site approved this retrospective case series.

The characteristics of these patients are provided in the Table. The median \[interquartile range (IQR)\] age was 72 \[62-74\] yr (range, 45-75 yr), and nine of the 15 patients (60%) were male. The indications for steroid administration were hypoxic respiratory failure (67%), vasoplegic shock on multiple vasopressors (20%), or both respiratory and cardiovascular failure (20%). Two non-intubated patients received steroids for impending respiratory failure with increasing inflammatory markers concerning for CRS. The median \[IQR\] day of steroid administration after symptoms onset was 14 \[12--15\] days. Nine patients (60%) received methylprednisolone, four patients (27%) received hydrocortisone, and two patients (13%) received dexamethasone. The median \[IQR\] dose of corticosteroids during the first 24 hr in methylprednisolone equivalents was 160 \[83-160\] mg. In almost all cases, there was a decrease in vasopressor requirement or an improvement in oxygenation after steroid administration. There was an average fall in CRP of 236 mg·L^−1^ with steroid administration (eFig. 1, available as Electronic Supplementary Material \[ESM\]). An average increase in the arterial partial pressure of oxygen/fraction of inspired oxygen (i.e., P/F) ratio of 44 was detected 24 hr after steroid administration (eFig. 2, available as ESM). Currently, four patients were discharged home, four patients remained in ICU, four patients were transferred to the medical ward, and three patients are deceased.TableCharacteristics of 15 critically ill patients with COVID-19 who received corticosteroidsNoAge (yr)SexTime from symptoms to steroids (days)Steroid administeredDosage of steroid over first 24 hr -- Methylprednisolone equivalents (mg)IndicationClinical change 24 hr post therapyCRP\
(mg L^−1^)P~a~O2/F~I~O2 ratioCurrent condition172M12Methylprednisolone160VasoplegiaImproved hemodynamics348→163N/AWard272M16Methylprednisolone160Severe ARDSModerate ARDS341→973→130ICU362M10Hydrocortisone40Severe ARDSModerate ARDS455→21777→150Ward466M14Methylprednisolone160Severe ARDSSevere ARDS378→12171→77Deceased553F8Methylprednisolone160Severe ARDSModerate ARDS466→15092→100ICU663F14Hydrocortisone60Severe ARDS & vasoplegiaModerate ARDS and improved hemodynamics556→4983→110ICU766M16Hydrocortisone60VasoplegiaImproved hemodynamics293→85N/AICU878M13Methylprednisolone160Severe ARDS & vasoplegiaModerate ARDS and improved hemodynamics425→14960→110Deceased955M14Dexamethasone106.75L NP1L NP210→61N/AHome1074M13Dexamethasone106.75L NP4L NP297→104N/AHome1172F14Methylprednisolone160Severe ARDSModerate ARDS115→4887→155Home1275M12Hydrocortisone40VasoplegiaImproved hemodynamicsN/AN/ADeceased1345F12Methylprednisolone160Severe ARDSModerate ARDS80→2282→145Home1475F22Methylprednisolone120Severe ARDSSevere ARDSN/A81→81Ward1573F17Methylprednisolone160Severe ARDSModerate ARDS368→8794→183WardSevere ARDS defined as PaO2/F~I~O2 ratio \< 100, Moderate ARDS defined as PaO~2~/F~I~O~2~ ratio ≥ 100 and \< 200. ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease; CRP = C-reactive protein; ICU = intensive care unit; N/A = not available; NP = nasal prongs; PaO~2~/F~I~O~2~ = arterial partial pressure of oxygen/fraction of inspired oxygen.

We present a subset of COVID-19 patients who presented with progressive respiratory failure along with progressive inflammatory biomarkers consistent with severe CRS. We found a significant clinical and biochemical association between corticosteroids and improved surrogate outcomes in late-onset CRS associated with COVID-19. Corticosteroids are indicated to treat CRS occurring from immune or chimeric antigen receptor therapy, but its use in weathering the cytokine storm in viral infection remains controversial, particularly if given early.[@CR4] Other coronaviruses have an inverted "V" distribution of viral shedding, peaking ten days after the onset of symptoms and then decreasing rapidly. Consequently, the clinical deterioration occurring after ten days may be caused by dysregulated inflammation and not the virus itself, offering a window of opportunity for therapeutic intervention.[@CR4]

Our report is limited by several important factors. There was no control group and therefore no randomization of intervention, we examined surrogate outcomes of uncertain clinical relevance, and there was likely selection bias in determining who received steroids and what dose they received. We report very few patients from a single centre, making it difficult to generalize our results to other hospitals even after consideration of the biases present. Additionally, exact criteria for CRS are not available and the prognostic importance of CRS in COVID-19 patients remains to be determined.

The fear of giving corticosteroids is related to a possible risk of decreased viral clearance with unclear clinical significance.[@CR5] Our report suggests the possibility of short-term clinical improvements with corticosteroids and it highlights the need for urgent high-quality studies to determine whether steroid administration may meaningfully affect the outcomes of critically ill COVID-19 patients.
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